Bone Marrow Transplantation最新文献

{"title":"Comparison of GvHD prophylaxis regimens based on in vivo T-cell depletion (ATG vs. alemtuzumab) in patients with AML undergoing allo-HCT from unrelated donors with intermediate transplant conditioning intensity protocols: a registry study on behalf of the EBMT acute leukemia working party.","authors":"Jesús Duque-Afonso, Jürgen Finke, Allain-Thibeault Ferhat, Jacques-Emmanuel Galimard, Francesca Kinsella, Deborah Richardson, Friedrich Stölzel, Eleni Tholouli, Caroline Besley, Matthias Eder, Emma Nicholson, Robert Zeiser, Adrian Bloor, Charles Crawley, Katherine Clesham, Jennifer Byrne, Patrick Medd, Elisa Sala, Caroline Pabst, Jan Vydra, Eva Maria Wagner-Drouet, Alain Gadisseur, Alexandros Spyridonidis, Eolia Brissot, Arnon Nagler, Mohamad Mohty, Fabio Ciceri","doi":"10.1038/s41409-026-03016-7","DOIUrl":"10.1038/s41409-026-03016-7","url":null,"abstract":"<p><p>Allogeneic hematopoietic cell transplantation is a potentially curative therapy for acute myeloid leukemia (AML), but its success is limited by graft-versus-host disease (GvHD). Optimal in vivo T-cell depletion strategies for GvHD prophylaxis given with conditioning regimens remain under investigation. We compared antithymocyte globulin (ATG) and alemtuzumab as GvHD prophylaxis in adult AML patients in complete remission (CR1/CR2) undergoing allogeneic cell transplantation from unrelated-donors conditioned with intermediate-intensity regimens. From the EBMT registry, 1545 patients were identified (710 ATG; 835 alemtuzumab). Patients receiving ATG were slightly older and had higher comorbidity scores, but groups were otherwise comparable. At 3 years, ATG was associated with superior overall survival (58.3% vs. 50.4%, p = 0.03) and leukemia-free survival (52.1% vs. 45.7%, p = 0.014). ATG recipients also demonstrated significantly lower relapse incidence (21.9% vs. 28.1%, p = 0.006), while non-relapse mortality remained similar between groups (26% vs. 26.3%, p = 0.46). Although ATG was associated with a higher incidence of acute GvHD, chronic GvHD rates did not differ significantly. In summary, for AML patients in complete remission receiving intermediate-intensity conditioning, ATG improved long-term survival and reduced relapse risk compared with alemtuzumab, despite increased acute GvHD. These findings support ATG as an effective GvHD prophylactic option in this setting.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148928930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early deterioration and subsequent recovery of nursing complexity after CAR-T therapy: a prospective score-based analysis.","authors":"Eugenio Galli, Ilaria Pansini, Elisabetta Schifitto, Alessandro Corrente, Pasquale Rea, Giorgia Brizzi, Alessio Capitani, Teresa Laviano, Fabio Lamberti, Cinzia Sechi, Marco Cioce, Elisabetta Metafuni, Sabrina Giammarco, Federica Sorà, Patrizia Chiusolo, Simona Sica","doi":"10.1038/s41409-026-03031-8","DOIUrl":"https://doi.org/10.1038/s41409-026-03031-8","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148896579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterisation of TP53 mutational features and outcomes of acute myeloid leukaemia after allogeneic haematopoietic cell transplantation.","authors":"Martina Reuss, Thomas Meyer, Florian Ingelfinger, Rouven Hoefflin, Miriam Mozaffari Jovein, Hosna Baniadam, Dietmar Pfeifer, Justus Duyster, Jesus Duque-Afonso, Kristina Maas-Bauer, Ralph Wäsch, Armin Zebisch, Annkristin Heine, Tobias Holderried, Jürgen Finke, Claudia Wehr, Robert Zeiser, Tobias Wertheimer","doi":"10.1038/s41409-026-03029-2","DOIUrl":"https://doi.org/10.1038/s41409-026-03029-2","url":null,"abstract":"<p><p>TP53 mutations define a clinically distinct subset of acute myeloid leukaemia (AML) associated with complex cytogenetics and therapy resistance. We performed a retrospective single-centre analysis of 61 consecutive TP53-altered AML patients undergoing first allogeneic haematopoietic cell transplantation (allo-HCT) at the Medical Center Freiburg (2007-2025), compared with 636 TP53-wild-type controls. TP53-altered patients had markedly inferior overall survival (median 379 vs. 1694 days; 5-year OS 18% vs. 50%; p < 0.001). Excess relapse was the primary driver (5-year cumulative incidence 55% vs. 33%; p < 0.001), whereas non-relapse mortality did not differ (28.5% vs. 23%; p = 0.426). On multivariable Cox analysis, TP53 alteration was the strongest independent predictor of inferior OS (HR 2.54, 95% CI 1.77-3.64; p < 0.001), and this association persisted after adjustment for cytogenetic risk and for the refined Disease Risk Index. In an exploratory hierarchical clustering analysis extended by seven patients from a second centre, two subgroups emerged: a del(17p)-enriched cluster (n = 12; median OS 5.7 months) and a TP53 point mutation-enriched cluster (n = 56; median OS 15.1 months). TP53-altered AML is confirmed as the strongest independent adverse prognostic factor after allo-HCT, and molecular heterogeneity within this subtype may inform trial stratification and targeted post-transplant interventions.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148891115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early infection post targeted chimeric antigen receptor T-cell therapy in patients with hematologic malignancies: a real-world, single-center, large-scale study.","authors":"Yi Zhou, Zhihua Liu, Rui Gao, Yang Xu, Depei Wu, Danya Shen","doi":"10.1038/s41409-026-03026-5","DOIUrl":"https://doi.org/10.1038/s41409-026-03026-5","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148891081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Growth retardation in long-term high-risk neuroblastoma survivors treated with high-dose chemotherapy: the impact of large vertebral irradiation and gonadal damage.","authors":"Sandrine Haghiri, Eleni Karamouza, Noura Sellami, Chiraz El-Fayech, Céline Khouri, Laura Lenez, Eric Thebault, Julie Allard, Cécile Thomas-Teinturier, Dulanjalee Kariyawasam, Claudia Pasqualini, Christelle Dufour, Stephanie Bolle, Nadia Haddy, Florent de Vathaire, Dominique Valteau-Couanet, Gwénaël Le Teuff, Brice Fresneau","doi":"10.1038/s41409-026-03030-9","DOIUrl":"https://doi.org/10.1038/s41409-026-03030-9","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148886402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allogeneic stem cell transplantation with post-transplantation cyclophosphamide in patients with acute myeloid leukemia achieving first complete remission after one versus two inductions: a study from the ALWP/EBMT.","authors":"Arnon Nagler, Ryszard Swoboda, Allain Thibeault Ferhat, Didier Blaise, Jurjen Versluis, Gwendolyn Van Gorkom, Maija Itala-Remes, Mercedes Colorado Araujo, Helene Labussiere-Wallet, Ibrahim Yakoub-Agha, Regis Peffault de Latour, Tobias Gedde-Dahl, Mieke W H Roeven, Edouard Forcade, Martin Carré, Patrice Chevallier, Deborah Desmier, Maurizio Musso, Jaime Sanz, Eolia Brissot, Ali Bazarbachi, Mohamad Mohty, Fabio Ciceri","doi":"10.1038/s41409-026-03012-x","DOIUrl":"https://doi.org/10.1038/s41409-026-03012-x","url":null,"abstract":"<p><p>Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a potentially curative treatment for high-risk acute myeloid leukemia (AML), and outcomes are strongly influenced by disease status at transplantation. In transplants using conventional graft-versus-host disease (GVHD) prophylaxis, outcomes also depend on the number of induction courses required to achieve first complete remission (CR1); however, this has not been evaluated in patients receiving post-transplant cyclophosphamide (PTCy). We retrospectively analyzed 677 adult AML patients transplanted in CR1 between 2012 and 2022 using PTCy-based GVHD prophylaxis. Outcomes were compared between patients achieving CR1 after one induction course (n = 518) and those requiring two courses (n = 159). Baseline characteristics, donor type, conditioning intensity, graft source, engraftment, and rates of acute and chronic GVHD were comparable between groups. Patients requiring two inductions had a higher 2-year cumulative incidence of relapse (27% vs. 19.3%; HR 1.75, p = 0.003). However, no significant differences were observed in 2-year overall survival (62.8% vs. 69%), leukemia-free survival (61.1% vs. 65%), GVHD-free/relapse-free survival (46.3% vs. 50.4%), or non-relapse mortality (11.9% vs. 15.7%). In AML patients receiving alloHSCT with PTCy, outcomes were largely similar regardless of whether CR1 was achieved after one or two-induction courses, with relapse incidence being higher in patients requiring 2 inductions.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148879090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pre-CAR-T B-cell-directed immunotherapy exposure and outcomes after CD19 CAR-T for large B-cell lymphoma: An EBMT registry analysis.","authors":"Jan Christian Schroeder, Christophe Peczynski, Philipp Berning, Eva Michel, Fizza Imran, Lucas Mix, Andreas Riedel, Robin Sanderson, Urban Novak, Ron Ram, Maria-Luisa Schubert, Maxime Delforge, David Beauvais, Daniela Taurino, Robin Noel, Lucia Lopez Corral, Almudena Cabero, Ralph Wäsch, Malte von Bonin, Peter Vandenberghe, Olaf Penack, Björn Chapuy, Avichai Shimoni, Barbara Dreta, Ulf Schnetzke, Eugenio Galli, Tobias Holderried, Claudia Lengerke, Norbert Schmitz, Wolfgang Andreas Bethge","doi":"10.1038/s41409-026-02979-x","DOIUrl":"https://doi.org/10.1038/s41409-026-02979-x","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148873005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Transplantation outcomes in Philadelphia-positive acute lymphoblastic leukemia with additional cytogenetic abnormalities: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.","authors":"Arnon Nagler, Jordi Esteve, Jacques-Emmanuel Galimard, Depei Wu, Erlie Jiang, Nathalie Dhedin, Anne Sirvent, Jan Vydra, Jakob Passweg, Bruno Lioure, Jaime Sanz, Jurjen Versluis, Yajing Xu, Cristina Castilla-Llorente, Rodrigo Martino Bufarull, Victoria Potter, Nour Ben Abdeljelil, Eolia Brissot, Ali Bazarbachi, Bipin Savani, Sebastian Giebel, Mohamad Mohty, Fabio Ciceri","doi":"10.1038/s41409-026-03022-9","DOIUrl":"10.1038/s41409-026-03022-9","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148863589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pregnancy outcomes in women conceiving after hematopoietic stem cell transplantation versus conventional chemotherapy for childhood or adolescent acute leukemia.","authors":"Loïc Guillerault, Paul Saultier, Carine Domenech, Stéphane Ducassou, Virginie Gandemer, Sandrine Visentin, Cécile Renard, Catherine Paillard, Marilyne Poiree, Aurélie Phulpin, Justyna Kanold, Marie-Dominique Tabone, Jean-Hugues Dalle, Laura Olivier, Corinne Armari-Alla, Sandrine Thouvenin, Isabelle Pellier, Pascal Auquier, Julie Berbis, Gérard Michel, Blandine Courbiere","doi":"10.1038/s41409-026-03019-4","DOIUrl":"https://doi.org/10.1038/s41409-026-03019-4","url":null,"abstract":"<p><p>Myeloablative conditioning before hematopoietic stem cell transplantation (HSCT) during childhood or adolescence reduces adult uterine volume, but its impact on future pregnancies remains uncertain. This multicenter study, nested within the LEA cohort, compared 86 pregnancies after HSCT (55 following total-body irradiation [TBI], 31 after high-dose alkylating agents) with 180 pregnancies after conventional chemotherapy in matched leukemia survivors (total: 266 pregnancies, 117 women). Twenty-nine percent of post-HSCT pregnancies required oocyte donation; 70% occurred spontaneously. Notably, 8% (n = 7) of HSCT pregnancies were unintended and ended in induced abortion. TBI markedly worsens obstetric outcomes. Live-birth rate was 35% after TBI vs. 61% after alkylating conditioning (p = 0.02). Compared with alkylating agents, TBI conferred higher risks of late pregnancy loss (24% vs. 3%), preterm birth (50% vs. 5%), low birth weight infants (33% vs. 0%), and postpartum hemorrhage (37% vs. 5%). By contrast, pregnancies after alkylating conditioning resembled those after conventional chemotherapy (live-birth 70% vs. 82%, p = 0.2) with no excess maternal or perinatal morbidity. Thus, TBI-based myeloablation during childhood or adolescence substantially compromises subsequent pregnancy outcomes, whereas high-dose alkylating conditioning appears obstetrically safe. These data may inform reproductive counseling and obstetric surveillance in female leukemia survivors treated with HSCT during childhood and adolescence.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148863633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world experience with posttransplant maintenance therapy in patients with myeloid neoplasms with active disease before allogeneic hematopoietic cell transplantation.","authors":"Hüseyin Sakiz, Raphael Battegay, Beatrice Drexler, Darius Juskevicius, Sabine Gerull, Michele Hoffmann, Roby Mathew, Francesca Matteazzi, Lucas Simeon, Georg Stussi, Jakob R Passweg, Joerg P Halter","doi":"10.1038/s41409-026-03028-3","DOIUrl":"https://doi.org/10.1038/s41409-026-03028-3","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148856906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}